Efficacy and Safety of FTY720 in Patients Who Receive a Kidney Transplantation
- Conditions
- Kidney Transplantation
- First Posted Date
- 2004-12-08
- Last Posted Date
- 2016-11-18
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 140
- Registration Number
- NCT00098735
Safety & Efficacy of Certican in Pediatric de Novo Renal Transplant Patients
- Conditions
- Kidney Transplantation
- First Posted Date
- 2004-12-06
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 45
- Registration Number
- NCT00098241
- Locations
- 🇧🇪
Dienst Pediatrie UZ Gasthuisberg, Herestraat 49, Leuven, Belgium
🇺🇸Columbus Children's Hospital, Columbus, Ohio, United States
Dose-Ranging Study in Patients With Chronic Obstructive Pulmonary Disease (COPD)
- Conditions
- COPD
- First Posted Date
- 2004-12-06
- Last Posted Date
- 2011-10-25
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 686
- Registration Number
- NCT00098228
- Locations
- 🇺🇸
Allergy Research Foundation , Inc, Los Angeles, California, United States
🇺🇸David Geffin UCLA School of Medicine, Los Angeles, California, United States
🇺🇸UAB Pulmonary Research, Birmingham, Alabama, United States
Famciclovir Pediatric Formulation in Children 1 to 12 Years of Age With Herpes Simplex Infection
- First Posted Date
- 2004-12-03
- Last Posted Date
- 2013-04-25
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 74
- Registration Number
- NCT00098059
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
🇺🇸Children's Medical Center of Dallas, Dallas, Texas, United States
🇺🇸Baylor College of Medicine/Texas Children's Hospital, Houston, Texas, United States
Safety/Efficacy of Everolimus and Neoral® in Adult Cardiac Transplant Patients With Established Allograft Vasculopathy
- Conditions
- Graft Rejection
- First Posted Date
- 2004-12-02
- Last Posted Date
- 2010-07-12
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT00097968
- Locations
- 🇺🇸
Midstate Cardiology, Nashville, Tennessee, United States
🇺🇸University of Minnesota, Fairfield University Hospital, Minneapolis, Minnesota, United States
🇺🇸Columbia Presbyterian Medical Center, New York, New York, United States
Safety and Efficacy of Aliskiren When Added to Standardized Losartan and Optimal Antihypertensive Therapy in Patients With Hypertension, Type 2 Diabetes and Proteinuria
- Conditions
- Diabetic Nephropathy
- First Posted Date
- 2004-12-02
- Last Posted Date
- 2017-05-17
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 496
- Registration Number
- NCT00097955
- Locations
- 🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
🇬🇧Investigative Site, London, United Kingdom
A Study of Safety, Tolerability & Efficacy of Certican in de Novo Heart Transplant (Tx) Patients
- Conditions
- Heart Transplantation
- First Posted Date
- 2004-12-02
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 199
- Registration Number
- NCT00098007
- Locations
- 🇺🇸
Cedar Sinai Medical Center, Los Angeles, California, United States
🇺🇸Newark Beth Israel Medical Center, Newark, New Jersey, United States
🇺🇸University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, United States
Long-term Study of Nateglinide+Valsartan to Prevent or Delay Type II Diabetes Mellitus and Cardiovascular Complications
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2004-12-01
- Last Posted Date
- 2023-11-08
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 9306
- Registration Number
- NCT00097786
Efficacy and Safety of Zoledronic Acid for the Treatment of Osteoporosis in Men
- Conditions
- Osteoporosis
- First Posted Date
- 2004-12-01
- Last Posted Date
- 2012-04-27
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 288
- Registration Number
- NCT00097825
- Locations
- 🇺🇸
St. Joseph Hospital, Bangor, Maine, United States
🇺🇸Osteoporosis and Clinical Trials Center, Hagerstown, Maryland, United States
🇺🇸UC Bone Health and Osteoporosis Center, Cincinnati, Ohio, United States
Switching Osteoporosis Patients Currently on Oral Bisphosphonate to Zoledronic Acid
- Conditions
- Osteoporosis
- First Posted Date
- 2004-12-01
- Last Posted Date
- 2012-04-27
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 220
- Registration Number
- NCT00097812
- Locations
- 🇺🇸
Arthritis Center of Nebraska, Lincoln, Nebraska, United States
🇺🇸University of Pittsburgh, Pittsburgh, Pennsylvania, United States
🇩🇪Novartis, Nuernberg, Germany